Conditions where inhibition of gastric acid secretion may be beneficial including GERD, PUD, NSAID-associated ulceration. Pathological hypersecretory states eg, Zollinger-Ellison syndrome.
GERD, erosive esophagitis 20-40 mg once daily for 4 wk, increased to 8 wk if necessary; 16 wk for erosive esophagitis. Maintenance: Continue w/ 20-40 mg daily. Alternatively, for recurring symptoms, 20 mg daily may be given. PUD 40 mg once daily for 2-4 wk (for duodenal ulcer) or 4-8 wk (for benign gastric ulcer). Prophylaxis for NSAID-associated ulceration 20 mg daily. Zollinger-Ellison syndrome Initially 80 mg daily up to 240 mg daily. Doses >80 mg should be given in 2 divided doses.
Prolonged use may lead to malabsorption of cyanocobalamin & atrophic gastritis. False +ve urine screening tests for tetrahydrocannabinol. Pregnancy & lactation. Childn.
Increased INR & prothrombin time w/ warfarin. Severe generalized myalgia & bone pain w/ MTX. May interfere w/ absorption of ketoconazole, ampicillin esters & Fe salts.
A02BC02 - pantoprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Sign Out
